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Purpose
The purpose of this study was to report clinical outcomes of ruthenium-106 (106Ru)
brachytherapy with or without additional local therapy for choroidal melanomas in Korean
patients.
Materials and Methods
A total of 88 patients diagnosed with choroidal melanomas were treated with 106Ru bra-
chytherapy between 2006 and 2012. Patients were divided into two groups according to
their tumor height: a large group (! 6 mm, n=50) and a small group (< 6 mm, n=38). Most
patients in the large group received combined therapy with local excision and/or transpupil-
lary thermotherapy. In general, 85-95 Gy was administered to the apex of the tumor, while
100 Gy was administered to the point 2-6 mm from the outer surface of the sclera for patients
undergoing combined therapy. 
Results
The median follow-up duration was 30 months. The 3-year local control rate was significantly
higher in the small group than in the large group (94% vs. 70%, p=0.047). The free from
distant metastasis (FFDM) rate and the overall survival (OS) rate were also higher in patients
in the small group (3-year FFDM, 97% vs. 76%; p=0.031 and 3-year OS, 97% vs. 72%;
p=0.036). A total of 13 patients underwent enucleation. The eye-preservation rate was also
higher in the small group (3-year eye-preservation rate, 94% vs. 70%; p=0.050), and tumor
height was a significant prognostic factor for eye-preservation.
Conclusion
106Ru brachytherapy showed favorable outcomes in small choroidal melanomas in Korean
patients. Although additional local treatment could improve eye-preservation rate for large
tumors, other strategies should be considered for disease control.
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Introduction
Choroidal melanomas are the most common primary 
intraocular malignancies in adults. However, choroidal
melanoma predominantly affects Caucasians, while it is very
rare in Asian populations. Despite the low incidence rates in
Asian populations, the tumors usually affect younger 
patients, tend to be larger, and present a high number of 
epitheloid cell types, resulting in a poorer prognosis in Asian
patients than in Caucasians [1]. 
Until the introduction of plaque brachytherapy using 
iodine 125 (125I) in the 1960s, enucleation was the standard
treatment for patients with choroidal melanomas. Although
the most important treatment goal is survival free of disease
recurrence, both patients and clinicians focus on preservation
of function and cosmetic appearance as well. The Collabora-
tive Ocular Melanoma Study confirmed the efficacy of pla-
que brachytherapy in a multicenter randomized trial inclu-
ding 1,317 patients, which did not reveal any inferiority of
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125I brachytherapy to enucleation, showing comparable 
5-year overall survival (OS) (81% vs. 82%) and 5-year cancer-
specific survival (89% vs. 91%) rates [2,3]. Moreover, 125I
brachytherapy did pose any additional risk of loss of visual
acuity in the fellow eye for at least 10 years after treatment
for choroidal melanoma [4]. Today, plaque brachytherapy is
a major modality for the management of choroidal melano-
mas because it is considered a reasonable eye-preserving 
alternative to enucleation. Although the benefits of plaque
brachytherapy may be reduced by impaired vision resulting
from radiation toxicity, this treatment modality has major
functional and cosmetic advantages.
Since its introduction, ruthenium-106 (106Ru) brachyther-
apy has been increasingly used for the treatment of small- to
medium-sized choroidal melanomas [5-7]. A 106Ru plaque
providing 1,000 Gy to the scleral surface conveys less than
100 Gy to a distance over 7 mm from the base, giving an 
insufficient radiation dose to the apex of large tumors [8,9].
Insufficient radiation to the apex could reduce the local
tumor control rate and increase the risk of recurrence, as well
as metastases and mortality. Several studies have reported
outcomes of the combination of the brachytherapy and
transpupillary thermotherapy (TTT) [10,11]. This combina-
tion therapy was introduced to enable eye-preservation for
patients with tumors larger than 5 mm, although it has also
been used to lessen the radiation dose for smaller tumors to
reduce the risk of radiation-related toxicities. Moreover, 
patients with insufficient tumor regression after brachyther-
apy or with recurrent tumors can be re-treated with TTT. 
Before the introduction of 106Ru plaques (Eckert & Ziegler
BEBIG, Berlin, Germany) to our institution in October 2006,
Gamma knife surgery (GKS) using a Leksell !-knife (Elekta
Instruments AB, Stockholm, Sweden) was the only eye-spar-
ing treatment for choroidal melanomas available in Korea.
Since 2006, we have primarily performed brachytherapy
with additional local treatment, including TTT and local 
excision, as eye-preserving therapy for choroidal melanomas.
This study was conducted to report the early clinical out-
comes of this eye-preserving treatment strategy for variable-
sized choroidal melanomas in Korean patients.
Materials and Methods
1. Patient selection
We identified 93 consecutive patients who were diagnosed
with uveal malignant melanomas and treated with 106Ru
brachytherapy between 2006 and 2012 in our institution. 
Patients with iris and ciliary body melanomas were excluded
(n=5) from this study. Because 106Ru plaque therapy is gen-
erally considered to treat tumors less than 6-7 mm in height,
our patients were divided into a large group (tumor height
" 6 mm) and a small group (tumor height < 6 mm) according
to their tumor height, as measured by ultrasonography.
2. Treatment methods
The treatment flow diagram is presented in Fig. 1. The
treatment was intended to deliver 85-95 Gy to the apex of the
tumor. However, owing to rapid radiation dose fall-off of
106Ru, 80% of the dose had already been absorbed at 5 mm
from the applicator. Thus, the dose to the apex is generally
considered insufficient for treatment of large tumors. The 
patients were informed of this limitation, but some patients
preferred brachytherapy anyway in an effort to preserve
their eyes. 
The three most frequently used applicators have diameters
Fig. 1. Treatment flow diagram. F/U, follow-up; TTT, transpupillary thermotherapy.
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of 15.3, 17.9, and 20.2 mm with active diameters of 13.5, 15.8,
and 18 mm, respectively. Applicators for the treatment of
juxtapapillary tumors (those located immediately adjacent
to the optic nerve) have a section cutout for the optic nerve. 
Some patients treated with brachytherapy received addi-
tional TTT and/or local excision. Local excision of the tumor
was conducted before brachytherapy on the same day as the
brachytherapy, which was delivered as an adjuvant treat-
ment. Planned TTT was performed with an adjuvant goal
after brachytherapy in patients who did not undergo local
excision. Unplanned TTT was performed if tumor regression
during follow-up was not sufficient after brachytherapy, 
regardless of initial tumor size. The first planned TTT proce-
dure was performed at the time of plaque removal using an
infrared diode laser and a slit-lamp delivery system. During
the follow-up period, additional TTT procedures were per-
formed in patients in an outpatient setting at intervals of 3
months. 
Enucleation was generally recommended for patients with
large tumors (height " 6 mm) because 106Ru brachytherapy is
not suitable for such tumors. However, for patients who 
refused enucleation, local excision of the tumor was per-
formed to reduce the height of the apex. If the tumor was
mainly located near the ciliary body, a transscleral tumor 
resection was performed, while if the tumor had a posterior
location and a basal diameter of less than 15 mm, endoresec-
tion with pars plana vitrectomy was performed. 
3. Evaluation of outcomes
The primary end-point was the eye-preservation rate (free
from enucleation). In addition, local control, OS and the rate
of distant metastasis were assessed. Survival was calculated
from the date of the insertion of the eye plaque to any event.
Patients lost to follow-up were censored. Late toxicity was
evaluated according to the Radiation Therapy Oncology
Group scale. 
Tumor response was evaluated with fundoscopy and 
ultrasonography, with a flat scar or a regressed lesion not
showing any signs of tumor activity representing tumor con-
trol. Local recurrence was defined as signs of tumor activity
on fluorescein angiography, or documented tumor growth
of more than 20% of the initial diameter or thickness 
(Response Evaluation Criteria in Solid Tumors criteria).
Metastases were detected through routine follow-up inves-
tigations (liver ultrasonography and blood chemistry tests)
or using 18F-fluorodeoxyglucose positron emission tomogra-
phy.
To assess the toxicity of treatment, regular follow-ups for
visual acuity and other ophthalmologic evaluations were
performed, in which complications such as retinopathy, mac-
ulopathy, optic neuropathy, retinal hemorrhage, and exuda-
tive retinal detachment were evaluated. In this study, only
issues that needed further treatment were defined as com-
plications. Vision was assessed using the World Health 
Organization (WHO) criteria, with low vision defined as a
visual acuity less than 1/3 and a vision < 0.1 considered legal
blindness.
4. Statistical analysis
The survival curves were estimated using the Kaplan-
Meier method, and comparisons between the two patients
groups were made with the log-rank test. Significant vari-
ables in univariate analysis (p < 0.05) were entered into a
multivariable Cox regression model to identify independent
predictors of eye-preservation rate, distant metastasis, and
OS. p < 0.05 were considered significant. Statistical analyses
were performed using SPSS ver. 20.0.0 (SPSS Inc., Chicago,
IL).
Results
1. Patient and treatment characteristics 
Between 2006 and 2012, 93 patients with choroidal melano-
mas were treated with 106Ru brachytherapy. Five patients with
iris and ciliary body tumors were excluded, leaving 88 patients
in the analysis. The median follow-up period was 30 months
(range, 2 to 79 months). The patients and treatment character-
istics are summarized in Table 1. The median age was 49 years
(range, 19 to 82 years). The initial visual acuity in the affected
eye was " 0.10 in 71% (n=63) and " 0.9 in 16% (n=14) of 
patients. Twenty-five (29%) patients were diagnosed with
legal blindness (< 0.1) prior to treatment and 10 patients (11%)
had visual impairment (< 20/60-20/200, WHO definition).
The median basal tumor diameter was 11.4 mm (range, 2.6 to
17.3 mm), and the median tumor height was 6.8 mm (range,
1.7 to 13.7 mm). The number of patients with a tumor height
" 6 mm (large group) was 50 (57%), and there were 38 (43%)
patients in the small group.
Combined therapy was used in the treatment of 75% (n=65)
of the patients. In the large group (tumor height " 6 mm), 96%
(n=48) of the patients received combined local therapy, while
in the small group, 44.7% (n=17) of the patients were treated
with combined treatment. The radiation dose was delivered
to 2-6 mm from the outer surface of the sclera for 47.7% (n=42)
of the entire sample, based on the extent of local excision and
use of TTT. For some of the patients who were treated with
TTT alone as an additional local therapy and for all patients
who did not receive additional treatment, the tumor apex was
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the prescription point.
Some patients (n=15, 39.5%) in the small group also received
additional TTT when tumor regression was deemed insuffi-
cient after brachytherapy, while two patients received local
excision before brachytherapy. One patient experienced rup-
ture of the tumor during vitrectomy and eventually received
internal choroidectomy. The other patient, who had a tumor
with a size of 12.5 mm (basal diameter)#5.9 mm (tumor height),
Table 1. Patient and treatment characteristics 
Characteristic Total (n=88) Small group (n=38) Large group (n=50)
Sex
Male 44 (50.0) 17 (44.7) 27 (54.0) 
Female 44 (50.0) 21 (55.3) 23 (46.0) 
Age (yr)
< 50 44 (50.0) 14 (36.8) 30 (60.0) 
" 50 44 (50.0) 24 (63.2) 20 (40.0) 
Initial visual acuity
< 0.1 (legal blindness) 25 (28.4) 9 (23.7) 16 (32.0) 
0.1-0.8 49 (55.7) 24 (63.2) 25 (50.0) 
" 0.9 14 (15.9) 5 (13.2) 9 (18.0) 
Pigmentation
Melanotic 75 (85.2) 32 (84.2) 43 (86.0) 
Amelanotic 13 (14.8) 6 (15.8) 7 (14.0) 
Proximity to optic nerve
Central/Juxtapapillary 32 (36.4) 15 (39.5) 17 (34.0) 
Peripheral 56 (63.6) 23 (60.5) 33 (66.0) 
Basal diameter (mm) 11.4 (2.6-17.3) 9.8 (4.0-15.2) 12.5 (3.0-17.3)
Tumor height (mm) 6.8 (1.7-13.7) 4.7 (1.7-6) 8.2 (6.3-13.7)
COMS stage
Small 4 (4.5) 3 (7.9) 1 (2.0) 
Medium 73 (83.0) 35 (92.1) 38 (76.0) 
Large 11 (12.5) 0 ( 11 (22.0) 
Visual acuity
< 0.1 25 (28.4) 9 (23.7) 16 (32.0) 
0.1-0.5 28 (31.8) 13 (34.2) 15 (30.0) 
0.6-0.8 21 (23.9) 11 (28.9) 10 (20.0) 
" 0.9 14 (15.9) 5 (13.2) 9 (18.0) 
Combined treatment
No 23 (26.1) 21 (55.3) 2 (4.0) 
Yes 65 (73.9) 17 (44.7) 48 (96.0) 
TTT alone 39 (44.3) 15 (39.5) 24 (48.0) 
Tumor excision alone 22 (25.0) 1 (2.6) 21 (42.0) 
Both 4 (4.5) 1 (2.6) 3 (6.0) 
Prescription point
Apex 46 (52.3) 36 (94.7) 10 (20.0) 
2-6 mm from the sclera 42 (47.7) 2 (5.3) 40 (80.0) 
Dose to sclera (Gy)
< 500 42 (47.7) 22 (57.9) 24 (48.0) 
500-1,000 39 (44.3) 16 (42.1) 19 (38.0) 
> 1,000 7 (8.0) 0 ( 7 (14.0) 
Dose rate to sclera (cGy/hr) 578.5 (85.2-1,058) 486.1 (174.2-825.8) 800.2 (76.98-1,385)
Time to removal (hr) 85 (12-238) 85 (19.3-184) 96 (51-238)
Values are presented as number (%) or median (range). COMS, Collaborative Ocular Melanoma Study; TTT, transpulpillary
thermotherapy.
Yeona Cho, Brachytherapy for Choroidal Melanomas 
VOLUME 50 NUMBER 1 JANUARY 2018  141
was included in the small group in this study. However, he 
received local excision based on the decision of his physicians. 
2. Local control, distant metastasis, and OS
Local progression was diagnosed in 13 patients. The 3-year
local control rate was 80% (Fig. 2), and the 3-year local control
rate was significantly higher in the small group than in the
large group (94% vs. 70%, respectively; p=0.047). Salvage treat-
ments for local recurrence consisted of enucleation (n=12) and
additional TTT (n=1). 
Distant metastases were diagnosed in 12 patients, and one
patient died. The 3-year free from distant metastasis (FFDM)
rate was 84%, and the OS was 90% for all patients. The FFDM
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Fig. 2.  Local control of all patients (A) and two groups (B).
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and OS rates were also significantly higher in patients in the
small group (3-year FFDM, 97% vs. 76%; p=0.031 and 3-year
OS, 97% vs. 72%; p=0.036) (Fig. 3).
3. Eye preservation
Among the 88 patients, 13 eventually underwent enucle-
ation (12 patients for local recurrence and one patient for a
complication), resulting in a 3-year actuarial eye-preservation
rate of 80%. In the small group, only two patients underwent
enucleation because of tumor progression, giving a 3-year eye-
preservation rate of 94%. The eye-preservation rate was sig-
nificantly higher in this group when compared with the large
group (3-year eye-preservation rate, 94% vs. 70%, respectively;
p=0.050) (Fig. 4). 
4. Toxicities
The total rate of complications requiring further treatment
was only 7% (n=6). The types, number of cases, and interval
from brachytherapy are shown in Table 2. Two patients with
glaucoma received medical treatment (mannitol, avastin), and
one of them eventually received enucleation due to tumor pro-
gression, while the other underwent the Seton operation.
Other complications, including vitreous hemorrhage and reti-
nal detachment, were tolerable with proper intervention. One
patient in the large group who had a tumor with a height of 9
mm and received TTT after brachytherapy wanted to undergo
enucleation for phthisis 10 months after brachytherapy. The
dose to the sclera of this patient exceeded 1,000 Gy. 
Among the 63 patients with a pre-treatment visual acuity
greater than 0.10, 39 (62%) showed a deterioration of visual
acuity in the treated eye to < 0.10, which was considered to be
legal blindness. The 3-year functional eye-preservation rate
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Fig. 4.  Eye-preservation rate of all patients (A) and two groups (B).
Table 2. Radiation related toxicities
Radiation related toxicity No. of events (%) RTOG grade Interval (mo) Treatment
Glaucoma 3 (3) 2 7,14,15 Seton operation, medical treatment
Vitreous hemorrhage 2 (2) 12,14 Trans pars plana vitrectomy
Retinal detachment 1 (1) 3 20 Endolaser photocoagulation
Phthisis 1 (1) 3 10 Enucleation
Total 6 (7)
RTOG, Radiation Treatment Oncology Group. 
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was 58%, and 50% of tumors were close to the macula or optic
disc in these patients. 
5. Prognostic factors 
Cox regression analysis was used to evaluate prognostic fac-
tors for eye-preservation, distant metastasis, and OS (Table 3).
The following potential prognostic variables were examined
in the Cox proportional hazards models: age (< 50 years vs. 
" 50 years), initial visual acuity, tumor height (< 6 mm vs. " 6
mm), basal diameter, tumor location, and local treatment. The
significant prognostic factor for eye-preservation was tumor
height " 6 mm (hazard ratio, 9.560; 95% confidence interval,
1.235 to 73.984, p=0.042), while it was not significantly associ-
ated with distant metastasis or OS (p=0.135 and p=0.157, 
respectively). Other characteristics including age, initial visual
acuity, basal diameter, and tumor location did not affect the
patients’ prognosis. 
Discussion
In this study, we showed favorable local tumor control and
eye-preservation rates, especially in patients in the small
group (3-year local control, 94%; eye-preservation rate, 94%).
These results are comparable to those reported by other
groups for small or medium-sized tumors [12]. 
Although enucleation has been the most common primary
treatment for large choroidal melanomas, previous studies
showed that 125I brachytherapy could be a possible alterna-
tive treatment with regard to survival and local tumor con-
trol [13,14]. However, few studies have investigated the use
of beta-radiation emitting 106Ru to treat large choroidal mela-
nomas. 106Ru may not be effective because of its limited depth
of penetration, which could prevent it from reaching the apex
of thick tumors [15]. When compared with 125I, 106Ru has a
threefold faster radiation dose fall-off rate. The effective
amount of radiation of 80-100 Gy reaches less than 7 mm
when a 106Ru eye plaque with 1,000 Gy to the outer surface
of sclera is applied. Thus, a thicker tumor might receive an
insufficient radiation dose to its apex. On the other hand,
when the same radiation dose is delivered to the apex, the
base receives up to three times more radiation with 106Ru
than with 125I, which might cause extensive damage to the
sclera. Based on these findings, most patients in the large
group (96%) received additional local treatment with TTT,
tumor excision or both. 
Tumor necrosis caused by TTT is induced to a depth of 3
mm from the apex [16]. The effectiveness of combined use of
106Ru brachytherapy and TTT has been demonstrated in sev-
eral studies. As with TTT, the apex of the tumor is treated up
to 3 mm, while with brachytherapy, the highest dose is 
administered to the tumor base [10,17,18]. In addition,
among patients in the large group (height " 6 mm), local 
excision of the tumor was performed in 46% of patients. In
such cases, the prescription point was determined to be 2 mm
from the outer surface of the sclera. Augsburger et al. [19]
previously reported treatment of choroidal melanomas with 
extrascleral extension by surgical excision of the extrascleral
nodule followed immediately by plaque radiotherapy of the
intraocular tumor. They demonstrated the efficacy of a com-
bination of local excision and brachytherapy for the treat-
ment of choroidal melanomas showing that brachytherapy
alone was not sufficient. Adding these local treatments to
106Ru brachytherapy could increase local control in patients
with tumor heights exceeding 6 mm, which is generally 
regarded as the maximum thickness suitable for 106Ru bra-
chytherapy. Furthermore, it is expected that the radiation
dose to the scleral surface will need to be reduced to decrease
the risk of radiation-induced toxicities. 
Choroidal melanomas are relatively resistant to radiation,
and the brachytherapy dose needed to eradicate this tumor
is associated with a considerable risk of radiation damage to
ocular structures. In our analysis, the actuarial rate of radia-
tion related side effects that require further treatment was
7%. One of these patients underwent enucleation for persist-
ent phthisis after brachytherapy. This patient received a high
dose of radiation to the sclera exceeding 1,000 Gy with a high
dose rate (dose rate to sclera, 502.9 cGy/hr). Overall, 62% of
patients who had effective visual function upon initial diag-
nosis eventually experienced complete loss of their visual
acuity at their last follow-up, which is comparable to the 
results from other large series [20,21]. Half of these patients
had a tumor close to the macula or the optic disc. Radiation
induces occlusive vasculopathy with neovascularization and
retinal edema, resulting in deterioration of visual acuity that
continues for years after treatment. Increased doses and dose
rates to the macula and the optic disc are associated with
poorer visual outcomes [22]. 
According to our data, 80% of patients initially treated
with brachytherapy could be spared from enucleation. As 
expected, the eye-preservation rate of the large group was
lower than that of the small group (3-year eye-preservation
rate, 70% vs. 94%; p=0.047). Additionally, the overall out-
come of patients in our large group was lower than that of
Caucasian patients, who showed a 70%-90% eye-preserva-
tion rate after 125I brachy-therapy for large melanomas and a
82%-88% rate after 106Ru brachytherapy for any sized tumors.
Although 70% of patients in the large group were rescued
from enucleation, their oncologic outcome was still not sat-
isfactory (3-year FFDM, 76%; 3-year OS, 72%). This could be
explained by the distinct nature of the tumor in Asian 
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patients [23]. 
For these patients, other therapeutic approaches, including
proton therapy, which can access the full thickness of a large
tumor, may improve local control [24,25]. However, an 
effective method for reducing metastasis is still lacking, and
survival rates for these patients do not differ significantly 
between treatment methods, including brachytherapy, enu-
cleation, and GKS [1,13]. Hawkins reported that no effective
treatment for metastatic ocular melanoma has been found
during the process of organizing Collaborative Ocular
Melanoma Study trials [26]. However, a recent study repor-
ted the safety and efficacy of immuno-therapy with anti–
CTLA-4 antibody, an effective treatment for metastatic
cutaneous melanoma, for treatment of metastatic uveal
melanoma [27]. Based on the results of the present and pre-
vious studies, further investigation is warranted. Moreover,
early detection of distant metastases at the time of diagnosis
is essential to avoiding unnecessary local treatment and to
evaluation of potential adjunctive treatments.
In interpreting our data, the limitations of retrospective
analysis, including patients and treatment selection, must be
considered. Although the absolute indication for brachyther-
apy with additional local treatment is unclear, use of this
treatment seems to reliably be recommended for the 
improvement of local control. Another limitation lies in the
difficulty of evaluating toxicities, including determining
whether changes in the retina were attributed to radiation
alone or to tumor growth as well, and if these changes may
have existed at the time of initial diagnosis. Toxicity analysis
included only the patients requiring further treatment in this
study; therefore, the incidence of toxicities cannot be applied
directly to all patients with choroidal melanomas treated
with 106Ru brachytherapy. As the cohort is relatively small,
there were limitations in conducting a complete statistical
analysis. Additionally, it is necessary to verify the prognostic
factors identified in our data. Nevertheless, the strengths of
our study are that our patients received relatively homolo-
gous treatments based on their tumor size, and that they
were performed in a single institution. 
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